Photo by cdc from unsplash
Key Points Question Can plinabulin, a selective immunomodulating microtubule-binding agent, perform as well as pegfilgrastim to prevent chemotherapy-induced neutropenia and its clinical consequences? Findings In this randomized clinical trial of… Click to show full abstract
Key Points Question Can plinabulin, a selective immunomodulating microtubule-binding agent, perform as well as pegfilgrastim to prevent chemotherapy-induced neutropenia and its clinical consequences? Findings In this randomized clinical trial of 105 patients, plinabulin had comparable efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia with better safety findings, less bone pain, and a lower immunosuppressive profile. Meaning The findings of this study suggest that plinabulin’s same-day dosing compared with pegfilgrastim’s next-day dosing offers distinct advantages including reducing use of health care services.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!